TransMedics Addresses Misleading Short-Seller Claims with Confidence in Technology and Ethics

TransMedics Responds to Short-Seller Claims

TransMedics Group, Inc., a leading company in medical technology focusing on organ transplant therapy, has recently vocalized its strong rebuttal to inaccurate claims made in a report by Scorpion Capital. This report, released on January 10, 2025, has been criticized by TransMedics for its alleged intent to manipulate the market for financial gain. The company's response emphasizes the integrity of its practices, the capabilities of its technology, and its unwavering commitment to serving patients with end-stage organ failure.

In an official statement, TransMedics asserted that the assertions made in the report lacked merit and misrepresented essential aspects of their business and technological achievements. The company highlighted its OCS™ (Organ Care System) technology and NOP™ (National Organ Preservation) program, which have collectively facilitated over 7,000 successful organ transplants. This technology allows surgeons to make use of donor organs that would otherwise have been discarded due to limitations of previous methods related to logistics and preservation.

Dr. Waleed Hassanein, CEO and President of TransMedics, elaborated on the significance of their advancements in the transplantation field.